Introduction
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that has been studied for decades in preclinical and clinical research contexts. It is one of the most potent GHRP compounds identified, producing robust GH release through ghrelin receptor activation while also demonstrating direct cardioprotective properties that have made it a compound of interest beyond its GH-releasing activity.
What Is Hexarelin?
Hexarelin (also known as Examorelin) is a six-amino acid synthetic peptide that acts as a potent agonist of the growth hormone secretagogue receptor (GHS-R1a). It was developed in Italy in the early 1990s and studied extensively in human clinical research during the 1990s and early 2000s. Unlike many GHRPs, Hexarelin has accumulated a substantial body of human clinical data in addition to animal research.
GH Secretagogue Activity
Hexarelin is one of the most potent synthetic GHRP compounds, producing greater GH release on a molar basis than GHRP-6 or GHRP-2 in comparative studies. It acts through GHS-R1a in the pituitary and hypothalamus to stimulate GH release. Research has also shown that Hexarelin may have GH-releasing activity through mechanisms partially independent of GHRH, meaning its effects are not fully blocked by GHRH antagonists.
Cardiac Research Applications
One of the most distinctive aspects of Hexarelin research is its direct cardiovascular activity. Studies in animal models have demonstrated cardioprotective effects in ischemia-reperfusion injury models, suggesting Hexarelin acts on receptors in cardiac tissue beyond its central GHS-R1a activity. Research has identified CD36 as a potential receptor mediating some of Hexarelin’s cardiac effects — a finding that has driven interest in Hexarelin as a tool for studying cardiac repair and protection mechanisms.
GH Axis Desensitization
A notable finding in Hexarelin research is that continuous administration leads to more rapid GH axis desensitization compared to other GHRPs. Studies have shown that the GH response to Hexarelin diminishes with prolonged continuous use in animal and human models, which is a relevant design consideration for research protocols involving repeated administration.
Clinical Research History
Hexarelin has been studied in human subjects in the context of GH axis assessment, cardiac function research, and aging studies. Its potency and the availability of clinical data make it a well-characterized compound relative to many research peptides.
Storage and Handling
Hexarelin is supplied as a lyophilized powder, reconstituted with bacteriostatic water, and stored at -20°C before use. Post-reconstitution stability follows standard GHRP storage guidelines of 4°C with a 4 to 6 week usable window.
Conclusion
Hexarelin is a highly potent growth hormone secretagogue with a research profile that extends beyond GH release into direct cardiac applications. Its combination of GHS-R1a agonism and potential CD36-mediated cardioprotection makes it a uniquely valuable compound for researchers studying both the GH axis and cardiovascular biology.